BiotechTube
Inicure

Inicure

Stockholm, Sweden· Est.
inicure.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Inicure is a preclinical-stage biotech company pioneering a novel immunomodulatory approach to combat antibiotic-resistant infections. Its core technology involves small molecule FPR1 agonists that activate the NOX2 pathway in neutrophils, boosting the production of reactive oxygen species (ROS) to enhance bacterial killing and resolve inflammation. The company is targeting significant unmet needs in pyelonephritis, chronic wound infections, and MRSA, with a versatile platform applicable to both topical and systemic therapies. Inicure operates as a private entity, originating as a spin-off from Pronoxis AB, and is actively seeking collaborations to advance its programs.

Infectious Diseases

Technology Platform

Small molecule agonists of the Formyl Peptide Receptor-1 (FPR1) that activate the NOX2 pathway in neutrophils to enhance production of reactive oxygen species (ROS) for bacterial killing and inflammation resolution.

Opportunities

The global antimicrobial resistance crisis creates a urgent and growing demand for novel, non-traditional anti-infective therapies.
Inicure's host-directed approach, with a low predicted risk of driving bacterial resistance, positions it well in this market.
The platform's versatility for topical and systemic administration opens multiple high-value therapeutic avenues.

Risk Factors

The core scientific premise of boosting innate immunity via FPR1 agonism remains unproven in humans, carrying significant clinical development risk.
As a preclinical, private company, it is highly dependent on securing future funding to advance its programs.
It also faces competitive and regulatory uncertainties inherent to a first-in-class mechanism.

Competitive Landscape

Inicure operates in the emerging field of host-directed therapies for infections, competing with other modalities like bacteriophages, antibodies, and microbiome-based therapies. Its most direct competitors are other companies developing innate immune modulators (e.g., targeting other receptors or pathways like TLRs or complement), though FPR1-specific agonists appear to be a niche. It also competes indirectly with companies developing novel direct-acting antibiotics.

More companies in Sweden →